{"schema_version":"1.0","type":"article","title":"Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster","url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.md","lang":"en","date":"2026-08-06","publish_at":"2026-08-06T08:00:00+08:00","updated_at":"2026-08-06","category":"商業分析系列","topic":"商業分析系列","tags":["AnHorn Medicines","AH-001","Androgenetic Alopecia","Hair-Loss Drug","AR Degrader","PROTAC","Eli Lilly","Veradermics","Absci","Taiwan Biotech"],"summary":"Lilly has placed a $40 million bet on next-generation hair-loss drugs. With roughly 80 million U.S. patients still constrained by two legacy therapies, AH-001's Phase 2 data could become the next global asset-revaluation trigger.","key_points":[],"facts":[],"sections":["01 | Why Hair-Loss Drugs Have the Same Commercial Setup That Fueled the Weight-Loss Boom","02 | What the Market Underestimates Is Not the Patient Count, but the Demand That Has Never Been Unlocked","03 | Wall Street Has Already Voted: One Hair-Loss Drug Supported a Valuation Near $5 Billion","04 | Lilly Has Entered the Market: From Olumiant and Veradermics to ABS-201","05 | The Next Wave Could Be Triggered by Three New Treatment Classes at Once","06 | AH-001's Distinctive Position: At the Intersection of a New Mechanism, Topical Delivery, and Scalability","07 | Why AH-001 Could Create Major Value: The Key Is the Product Profile, Not AI","08 | AnHorn's Second Opportunity: One Hair-Loss Drug Could Validate the Entire Drug-Development Platform","09 | What Should Investors Watch? Three Milestones Will Determine the Next Revaluation","CONCLUSION | Lilly Has Bought Its Ticket. AnHorn Is Waiting for the Readout That Could Ignite the Market","REFERENCES"],"references":[{"title":"This article is based on public company disclosures, regulatory filings, clinical-trial registrations, and market materials. Company statements and market estimates are presented using the original publishers' definitions and assumptions.","source":"","date":"","url":""},{"title":"[Veradermics","source":"S-1: U.S. pattern hair-loss population, treatment penetration, satisfaction, and market estimates]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026001651/veradermicsincs-1.htm"},{"title":"[Veradermics","source":"Positive topline results from VDPHL01 Study 302 (April 27, 2026)]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/exhibit991-8xk.htm"},{"title":"[Investor's Business Daily","source":"One-day market reaction following Study 302]","date":"","url":"https://www.investors.com/news/technology/veradermics-ipo-stock-oral-rogaine/"},{"title":"[Eli Lilly","source":"Olumiant (baricitinib) for severe alopecia areata]","date":"","url":"https://olumiant.lilly.com/alopecia-areata"},{"title":"[Veradermics","source":"IPO prospectus: Lilly indication of interest (non-binding)]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026005505/veradermicsinc424b4.htm"},{"title":"[Absci","source":"Prospectus supplement: $40 million share allocation to Eli Lilly]","date":"","url":"https://investors.absci.com/static-files/5d70b681-4b5b-4830-9578-3a0e8473b3f4"},{"title":"[Absci","source":"ABS-201 for androgenetic alopecia / HEADLINE Phase 1/2a]","date":"","url":"https://www.absci.com/abs-201-case-study/"},{"title":"[ClinicalTrials.gov","source":"AH-001 Phase 1, NCT06927960]","date":"","url":"https://clinicaltrials.gov/study/NCT06927960"},{"title":"[AnHorn Medicines","source":"AH-001 completes U.S. Phase 1 (October 30, 2025)]","date":"","url":"https://www.anhornmed.com/zh-hant/news/ai-design-ah001-protein-degrader-phase1-complete/"},{"title":"[AnHorn Medicines","source":"AH-008 receives FDA IND clearance and CDE Index Case designation]","date":"","url":"https://www.anhornmed.com/news/ah008-ind-cipn/"},{"title":"[Kintor Pharmaceutical","source":"KX-826 Phase 3 met the primary endpoint]","date":"","url":"https://en.kintor.com.cn/news_details/22.html"},{"title":"[Kintor Pharmaceutical","source":"GT20029 China Phase 2 met the primary endpoint]","date":"","url":"https://en.kintor.com.cn/news_details/1803365125008502784.html"}],"images":[{"alt":"Veradermics Study 302 hair-count and patient-reported outcomes","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-01.png"},{"alt":"Global competitive landscape for next-generation hair-loss drugs","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-02.png"},{"alt":"Evolution from follicle stimulation to localized androgen-receptor degradation","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-03.png"},{"alt":"AnHorn AIMCADD and protein-degradation clinical-asset flywheel","url":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-06）。Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster。https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}